According to laboratory reports, the diabetes drug Qnexa, manufactured by pharmaceutical company Vivus Inc. is performing well at mid-stage clinical trials amongst patients with obesity .
Type 2 diabetes and obesity are closely linked, with many obese people facing a higher than average risk of developing type 2 diabetes . Those patients treated with Qnexa were found to improve blood pressure and further cardiovascular risk factors.
Over the course of the 28-week trial, Qnexa patients lowered triglyceride level and also improved their fasting blood glucose levels. Some 206 patients were tested with the drug, and were also found to lose more weight and lower waist circumferences.
A variety of new diabetes drugs are thought to be in the pipeline from both small-scale biotechnological companies and larger pharmaceutical firms. The diabetic drug industry is fiercely competitive and high value to those companies that develop effective medication .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…